HOUSTON--(BUSINESS WIRE)--Positron Corporation
(OTCBB:
POSC
-
News) The Centers for Medicare and Medicaid
Services (CMS) has released an advance copy of
CMS-1392-P Proposed Changes to the Hospital
Outpatient Prospective Payment System and
Calendar Year 2008 Payment Rates. The proposed
rule is expected to be published in the Federal
Register later this month.
CMS proposes to
reassign the PET/CT codes from APC 1511
– New Technology-Level
XI to APC 0308 –
Non-Myocardial Positron Emission Tomography
(PET) imaging. Therefore all the non-cardiac PET
CPT codes would be assigned to a single APC
0308, with a new payment rate of $1,107.22.
The proposed rule maintains the assignment of
all cardiac PET CPT codes to APC 0307
– Myocardial Positron
Emission Tomography (PET) imaging, with a new
payment rate of $2,711.25.
CMS-1392-P; Proposed Changes to the Hospital
Outpatient Prospective Payment System and
Calendar Year 2008 Payment Rates can be found
at:
http://www.cms.hhs.gov/hospitaloutpatientpps/hord/list.asp
Reimbursement information is provided by
Positron Corporation as general coding and
payment information. Note: This is a PROPOSED
rule, not a final rule, and there will be a
public comment period that closed on September
14, 2007. The final rule is expected to be
published in early November and the changes will
be effective January 1, 2008. Instructions on
how to submit comments are listed at the end of
this update.
Positron’s
President Mr. Joseph Oliverio stated,
“This proposed
increase in the reimbursement will provide us
with a great opportunity to quickly disseminate
Cardiac PET. This will help cardiologists
seriously look at adding PET to their practice.
Positron is ideally positioned to offer them as
an economical compliment to SPECT.”
About Positron
Positron Corporation designs, manufactures,
markets and supports advanced cardiac molecular
imaging devices utilizing single photon emission
computed tomography (SPECT) and positron
emission tomography (PET). The company’s
molecular imaging systems incorporate patented
and proprietary software and hardware technology
for the diagnosis and treatment of patients with
heart disease. Positron
Corporation offers unique combination of low
cost technology and disease specific software
solutions differentiating themselves
from all other medical device manufacturers.
Additional information may be found at
http://www.positron.com and
http://www.is2medical.com.
Forward Looking Statements:
Statements in this document contain certain
forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and
the Securities Exchange Act of 1934, as amended.
These statements are based on many assumptions
and estimates and are not guarantees of future
performance and may involve known and unknown
risks, uncertainties and other factors which may
cause the actual results, performance or
achievements of Positron Corporation to be
materially different from future results,
performance or achievements expressed or implied
by such forward-looking statements. The words
“expect,”
“anticipate,”
“intend,”
“plan,”
“believe,”
“seek,”
“estimate,”
and similar expressions are intended to identify
such forward-looking statements. Our actual
results may differ materially from the results
anticipated in these forward-looking statements
due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in
our filings with the Securities and Exchange
Commission.
For further information please contact
Positron Corporation at (281) 492-7587.
